Optinate: Uses, Dosage & Side Effects
An oral nitrogen-containing bisphosphonate used to treat and prevent osteoporosis, glucocorticoid-induced bone loss, and Paget's disease of bone
Optinate (risedronate sodium) 5 mg is a prescription-only oral bisphosphonate used to treat and prevent osteoporosis in postmenopausal women and men, to prevent bone loss in patients receiving long-term systemic corticosteroids, and to treat Paget's disease of bone. It works by selectively inhibiting the osteoclasts that break down bone, thereby increasing bone mineral density and reducing the risk of vertebral and hip fractures. The 5 mg strength is the daily dosing formulation, taken first thing in the morning with plain water while the patient remains upright. Multiple large randomized trials have shown that risedronate reduces vertebral fracture risk by 41–49% and non-vertebral fracture risk by approximately 33–39% within the first three years of treatment.
Quick Facts: Optinate 5 mg
Key Takeaways
- Optinate (risedronate sodium) 5 mg is a nitrogen-containing bisphosphonate that increases bone mineral density and reduces the risk of vertebral and hip fractures in patients with osteoporosis.
- The daily 5 mg tablet must be taken on an empty stomach with a full glass of plain water, at least 30 minutes before any food, other drink, or medication; remain upright for 30 minutes after dosing to avoid oesophageal irritation.
- Optinate is contraindicated in severe renal impairment (creatinine clearance below 30 mL/min), uncorrected hypocalcaemia, pregnancy and breastfeeding, and in patients who cannot remain upright for at least 30 minutes.
- Rare but serious adverse events include atypical femoral fractures, osteonecrosis of the jaw, and severe upper gastrointestinal reactions; a dental review before starting therapy and good oral hygiene throughout treatment reduce the risk.
- Because risedronate has a very long skeletal half-life (approximately 480 hours in plasma, with persistence in bone for years), many patients will benefit from a reassessment and possible drug holiday after 3–5 years of continuous treatment.
What Is Optinate and What Is It Used For?
Optinate contains the active substance risedronate sodium, a nitrogen-containing bisphosphonate. Bisphosphonates are a well-established class of medicines that have been the mainstay of osteoporosis pharmacotherapy for over two decades. Structurally, they are stable synthetic analogues of pyrophosphate in which the central oxygen atom is replaced by a carbon atom, producing a P–C–P backbone that resists enzymatic degradation. Risedronate belongs specifically to the subgroup known as amino-bisphosphonates, which contain a nitrogen-bearing side chain. This structural feature gives risedronate a substantially higher potency than older, non-nitrogen bisphosphonates (such as etidronate) and allows it to work through a different intracellular mechanism.
Once absorbed from the gastrointestinal tract, risedronate rapidly distributes to bone surfaces, where it binds with high affinity to hydroxyapatite crystals in the bone matrix, particularly at sites of active bone remodelling. When osteoclasts subsequently attempt to resorb bone, they take up the drug. Inside the osteoclast, risedronate inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. This blocks the prenylation of small GTP-binding proteins (such as Ras, Rho, Rac and Rab) that are essential for osteoclast function, cytoskeletal organisation and survival. The end result is reduced osteoclast activity, decreased bone resorption, and a gradual shift in bone remodelling in favour of net bone formation.
Clinically, this translates into measurable gains in bone mineral density (BMD) at the spine and hip, improvements in bone microarchitecture and a reduction in fracture risk. In the pivotal VERT (Vertebral Efficacy with Risedronate Therapy) and HIP trials, risedronate reduced the incidence of new vertebral fractures by 41–49% and non-vertebral fractures by approximately 33–39% over three years in postmenopausal women with osteoporosis. The HIP trial specifically showed a 40% reduction in hip fracture risk among women aged 70–79 years with confirmed osteoporosis.
Optinate 5 mg is the daily-dose formulation of risedronate. Other strengths and dosing schedules also exist in the wider risedronate product family, but the 5 mg daily tablet is particularly useful in patients who prefer a regular daily routine, in those who do not tolerate weekly or monthly high-dose regimens, and in patients with Paget's disease who require an intensive short course of therapy.
Optinate 5 mg is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and by regulatory authorities in numerous other countries for the following indications:
- Treatment of postmenopausal osteoporosis: To reduce the risk of vertebral and hip fractures in postmenopausal women with established osteoporosis.
- Prevention of postmenopausal osteoporosis: To maintain bone mineral density in postmenopausal women at increased risk of osteoporosis, such as those with low bone mass, early menopause or a strong family history.
- Treatment of osteoporosis in men: To increase bone mineral density in men with osteoporosis who are at high risk of fracture.
- Prevention and treatment of glucocorticoid-induced osteoporosis (GIO): In women and men who are initiating or continuing long-term oral corticosteroid therapy (usually defined as at least 7.5 mg prednisolone-equivalent daily for three months or more).
- Treatment of Paget's disease of bone (osteitis deformans): To promote remission, normalise serum alkaline phosphatase, reduce pain and limit structural complications.
Osteoporosis is a systemic skeletal disorder characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. The most common fractures involve the vertebrae, hip and wrist, and they can have a profound impact on independence, mobility and mortality, particularly after a hip fracture. According to the International Osteoporosis Foundation, one in three women and one in five men over the age of 50 worldwide will suffer an osteoporotic fracture in their remaining lifetime. Effective pharmacological treatment, alongside adequate calcium and vitamin D intake, weight-bearing exercise and fall-prevention strategies, forms the cornerstone of modern fracture prevention.
Paget's disease of bone is a localised disorder of bone remodelling in which one or more skeletal sites (most commonly the pelvis, spine, skull, femur and tibia) undergo excessive, disorganised bone turnover. The resulting bone is larger but structurally weaker, leading to bone pain, deformity, arthritis of adjacent joints and, less commonly, fractures, hearing loss (when the skull is involved) or neurological compression syndromes. Optinate 5 mg is given at a higher intensity (30 mg daily for two months) in Paget's disease, which produces sustained biochemical remission in most patients.
Unlike systemic hormone therapies, bisphosphonates such as risedronate localise selectively to bone. Only about 50% of an absorbed dose reaches the skeleton; the remainder is excreted unchanged in the urine. This bone-selective action is why the drug can continue to exert an anti-resorptive effect long after treatment has ended, which is the rationale for the "drug holiday" strategy used in long-term management.
What Should You Know Before Taking Optinate?
Contraindications
There are a small number of situations in which Optinate must not be used. These absolute contraindications reflect well-documented safety concerns and must be reviewed carefully before treatment is started.
- Hypersensitivity: Optinate must not be taken by anyone with a known allergy to risedronate sodium or to any of the tablet's excipients.
- Hypocalcaemia: Low serum calcium must be corrected before starting bisphosphonate therapy, because risedronate can exacerbate hypocalcaemia and precipitate tetany, paraesthesia or cardiac arrhythmias.
- Severe renal impairment: Risedronate is primarily eliminated by the kidneys, and it is contraindicated in patients with a creatinine clearance below 30 mL/min due to accumulation and a lack of safety data in this group.
- Pregnancy and breastfeeding: Risedronate crosses the placenta in animal studies and has been associated with skeletal effects in the offspring; it should not be used during pregnancy or while breastfeeding.
- Inability to stand or sit upright for at least 30 minutes: Because retained tablets can cause severe oesophageal injury, Optinate must not be prescribed to patients who are unable to remain upright for the required 30-minute window after dosing.
Warnings and Precautions
Bisphosphonates can cause local irritation of the upper gastrointestinal mucosa. Severe oesophageal reactions (including oesophagitis, ulcers and strictures, sometimes with bleeding and rarely with oesophageal perforation) have been reported, particularly when dosing instructions are not followed. Stop Optinate and contact your doctor at once if you develop new or worsening difficulty or pain on swallowing, pain behind the breastbone, severe heartburn or vomiting of blood.
Before starting Optinate, and periodically during treatment, discuss the following situations with your healthcare provider, as they may change the benefit–risk balance or require additional monitoring:
- Active upper gastrointestinal disease: Patients with recent severe oesophagitis, reflux disease, peptic ulcer, gastric surgery, or strictures of the oesophagus require careful assessment. Optinate may still be used with caution in many of these patients if dosing instructions are followed meticulously.
- Mineral deficiencies: Adequate calcium and vitamin D intake is essential for bone health. If dietary intake is insufficient, supplements should be prescribed alongside Optinate, although they must never be taken at the same time of day as the tablet.
- Renal impairment: In mild-to-moderate impairment (creatinine clearance 30–60 mL/min) no dose adjustment is usually needed, but renal function should be monitored.
- Osteonecrosis of the jaw (ONJ): This rare condition involves exposed, non-healing bone in the mouth. The absolute risk with oral bisphosphonates for osteoporosis is very low (estimated at 1 in 10,000 to 1 in 100,000 patient-years), but risk is increased by invasive dental procedures, poor dental hygiene, periodontal disease, smoking, corticosteroid use and cancer. A dental examination and completion of any necessary dental work before starting therapy are strongly recommended.
- Atypical femoral fractures: Low-trauma, subtrochanteric or diaphyseal femoral fractures have been reported with long-term bisphosphonate use, often after five or more years of therapy. Any new thigh, hip or groin pain during treatment should prompt clinical assessment and imaging.
- External auditory canal osteonecrosis: Rare cases of ear canal osteonecrosis have been reported with bisphosphonates. Patients should report any ear pain, discharge or chronic ear infection during treatment.
- Musculoskeletal pain: Severe and occasionally incapacitating bone, joint or muscle pain has been reported, sometimes weeks or months after starting therapy. Symptoms usually resolve after discontinuation, although recurrence has occurred on rechallenge.
- Eye inflammation: Uveitis, iritis and scleritis have been reported rarely; ophthalmology review is warranted if new ocular symptoms develop.
Your doctor will typically monitor serum calcium and vitamin D status, kidney function and, where indicated, bone mineral density (using dual-energy X-ray absorptiometry) to guide the duration of therapy.
Other Medications
Tell your doctor and pharmacist about all medications you are currently taking, have recently taken or plan to take, including prescription drugs, over-the-counter medicines, vitamins, mineral supplements and herbal products. The absorption of risedronate is strongly affected by any substance containing polyvalent cations (calcium, magnesium, aluminium, iron, zinc), so timing separation is essential.
Pregnancy and Breastfeeding
Optinate should not be used during pregnancy. Bisphosphonates cross the placenta in animal studies and have been shown to cause skeletal abnormalities, hypocalcaemia and perinatal mortality in animal offspring. Human data are limited but concerning, and because risedronate is retained in the skeleton for years after discontinuation, the potential for exposure during a future pregnancy cannot be ruled out. Women of childbearing potential should use effective contraception during treatment and discuss family planning with their doctor.
It is not known whether risedronate is excreted in human breast milk. Because of the potential for accumulation in the nursing infant's developing skeleton, Optinate should not be used while breastfeeding.
Driving and Operating Machinery
Risedronate has no known direct effect on alertness, reaction time or coordination, and no specific restrictions apply to driving or operating machinery. However, some patients report dizziness, especially after the first few doses, and rare cases of blurred vision have been described. If you experience any such symptoms, avoid driving or operating machines until they have resolved.
Important Information About Ingredients
Each Optinate 5 mg film-coated tablet contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. The tablet coating contains small amounts of excipients that can, very rarely, cause local allergic reactions in susceptible individuals.
How Does Optinate Interact with Other Drugs?
Pharmacokinetic interactions with risedronate are primarily related to its absorption, which is already very low (approximately 0.63% under fasting conditions) and is further reduced by anything taken at the same time that contains polyvalent cations. There are relatively few metabolic interactions because risedronate is not metabolised and does not affect cytochrome P450 enzymes. Pharmacodynamic interactions – which influence the risk of specific adverse effects – are also clinically important, particularly in the context of gastrointestinal safety.
Major Interactions
| Interacting Drug / Substance | Effect | Clinical Significance |
|---|---|---|
| Calcium, iron, magnesium or zinc supplements | Form insoluble complexes with risedronate in the gut, dramatically reducing absorption | Separate by at least 30 minutes – ideally take Optinate in the morning and supplements later in the day |
| Antacids containing calcium, magnesium or aluminium | Chelation reduces risedronate bioavailability | Must not be taken within 30 minutes of Optinate |
| Dairy products and fortified foods/drinks | Calcium, magnesium and phosphates reduce absorption when taken together | No food, drinks (other than plain water) or milk until at least 30 minutes after dosing |
| NSAIDs (e.g. ibuprofen, naproxen, diclofenac) | Additive gastrointestinal irritation; increased risk of ulcers and bleeding | Use with caution, especially long-term; monitor for dyspepsia and bleeding |
| Aspirin (especially higher analgesic doses) | Increased risk of upper gastrointestinal adverse events | Low-dose cardioprotective aspirin is generally acceptable; discuss high-dose use with your doctor |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole) | Possible small reduction in risedronate absorption and observational association with higher fracture risk during long-term combined use | Continue PPI if clinically required; review the ongoing need periodically |
| H2-receptor antagonists (ranitidine, famotidine) | No clinically significant effect on risedronate pharmacokinetics | Can generally be co-prescribed without dose adjustment |
| Systemic corticosteroids (prednisolone, dexamethasone) | Independent cause of bone loss; also increases gastrointestinal adverse-event risk | Bisphosphonates are specifically indicated for prevention of steroid-induced osteoporosis; monitor for GI symptoms |
| Hormone replacement therapy (HRT) | No pharmacokinetic interaction; combined effects on bone are broadly additive | Combination is generally not needed; guidelines usually recommend one or the other |
| Oestrogens in oral contraceptives | No pharmacokinetic interaction | Can be co-administered; bisphosphonates are rarely used in women of childbearing age |
| Warfarin and other oral anticoagulants | No direct pharmacokinetic interaction | However, falls-related injury risk should be reviewed in older patients |
Because risedronate is not metabolised by the liver and is not bound extensively to plasma proteins, it does not participate in the classical cytochrome P450 or protein-binding interactions that complicate many other drug regimens. The central interaction principle for patients is therefore simple but critical: nothing in the stomach at the same time as the tablet.
What Is the Correct Dosage of Optinate?
Optinate is always taken orally. The dosing regimen is defined by the indication, and adherence to the specific administration instructions is at least as important as the dose itself: because oral bioavailability is very low, taking the tablet incorrectly can reduce absorption to almost zero and eliminate the clinical benefit.
Adults
Postmenopausal Osteoporosis – Treatment and Prevention
Dose: Optinate 5 mg once daily
Duration: Typically 3–5 years, with reassessment of bone mineral density and fracture risk thereafter
Supplemental calcium (usually 1,000–1,200 mg elemental calcium per day from diet plus supplements) and vitamin D (typically 800–1,000 IU daily) should be ensured, but must not be taken at the same time of day as Optinate.
Osteoporosis in Men
Dose: Optinate 5 mg once daily
Duration: Individualised based on baseline fracture risk and BMD response; commonly 3–5 years initially
Underlying causes of secondary osteoporosis (hypogonadism, chronic corticosteroid use, alcohol excess) should be investigated and addressed in parallel.
Glucocorticoid-Induced Osteoporosis (GIO)
Dose: Optinate 5 mg once daily
Duration: For as long as systemic corticosteroid therapy is ongoing, reviewed at least annually
Indicated in adults initiating or continuing long-term oral corticosteroids (generally ≥7.5 mg prednisolone-equivalent per day for three months or more). Treatment should start as early as possible after beginning high-dose steroids, when bone loss is most rapid.
Paget's Disease of Bone
Dose: 30 mg once daily (six Optinate 5 mg tablets taken as a single dose) for 2 months
Duration: A single two-month course; repeat courses after a minimum six-month treatment-free interval if disease reactivates (e.g. serum alkaline phosphatase rises or symptoms recur)
Although 30 mg daily can also be delivered using a 30 mg Actonel-brand tablet where available, the 5 mg tablet provides flexibility where only this strength is on hand.
How to Take Optinate Correctly
To protect the oesophagus and to maximise the already-limited absorption of risedronate, follow these instructions meticulously:
- Time of day: Take the tablet after getting out of bed in the morning, before breakfast and before any other medicine.
- With what: Swallow the tablet whole with a full glass (at least 120 mL, ideally 180–240 mL) of plain tap water. Mineral water, sparkling water, coffee, tea, juice and milk must not be used.
- Posture: Take the tablet while sitting upright or standing. Do not take it while lying down.
- Do not chew, crush or suck the tablet: Contact between dissolving risedronate and the oral or oesophageal mucosa can cause ulceration.
- Wait: Remain upright (sitting, standing or walking) and do not consume any food, drink (other than more plain water) or other oral medicines for at least 30 minutes.
- Then eat: After the 30-minute interval you may eat your normal breakfast and take other medications, including calcium and vitamin D supplements.
Children
Optinate is not recommended for use in children and adolescents below 18 years of age. Safety and efficacy data in paediatric osteoporosis are limited, and specialist input is required when bisphosphonate therapy is being considered for conditions such as osteogenesis imperfecta or secondary paediatric osteoporosis. In such cases, treatment is initiated and monitored in a specialist centre using protocols that differ from the adult osteoporosis regimen.
Elderly Patients
No dose adjustment is required for patients aged 65 years or older, in whom most of the clinical trial evidence has been generated. Older patients are, however, more likely to have reduced renal function, polypharmacy (including NSAIDs and corticosteroids), poor dentition and swallowing difficulties – all of which influence the safety of bisphosphonate therapy. Careful medication reconciliation, assessment of swallowing and renal function (estimated GFR), and a dental review before treatment are particularly important in this group.
Renal and Hepatic Impairment
No dose adjustment is needed in mild-to-moderate renal impairment (creatinine clearance 30–60 mL/min), although renal function should be monitored. Optinate is contraindicated if creatinine clearance is below 30 mL/min. Because risedronate is not metabolised by the liver, no dose adjustment is required in hepatic impairment.
Missed Dose
If you forget your morning dose, do not take it later in the day with food. For the daily 5 mg regimen, simply skip the missed dose and take your next dose as usual the following morning. Do not take two tablets on the same day to make up for a forgotten dose. If you frequently forget your daily tablet, discuss this with your doctor; a weekly or monthly dosing regimen may be easier to remember.
Overdose
There is limited information on acute overdose with risedronate. A decrease in serum calcium may occur, potentially causing paraesthesia (tingling), muscle cramps, tetany, confusion or, rarely, cardiac arrhythmias. Significant upper gastrointestinal symptoms (nausea, vomiting, dyspepsia or oesophageal erosion) may also occur. Administration of milk or antacids containing calcium, magnesium or aluminium may help bind unabsorbed risedronate. Standard measures for managing hypocalcaemia (intravenous calcium gluconate if severe) should be instituted under medical supervision. Do not induce vomiting because of the risk of worsening oesophageal irritation. If you or someone else has taken too much Optinate, contact your local poison control centre or emergency department immediately.
The most common reason for apparent treatment failure with oral bisphosphonates is incorrect administration – taking the tablet with coffee, juice or breakfast, lying back down, or taking it with calcium or iron tablets. Before concluding that Optinate is not working, your doctor will almost always review how you are taking it. If in any doubt, ask your pharmacist for a step-by-step demonstration.
What Are the Side Effects of Optinate?
Like all medicines, Optinate can cause side effects, although not everyone gets them. The adverse-event profile of risedronate has been characterised in tens of thousands of patients across randomised controlled trials and long-term observational studies. Most side effects are mild and transient, and many (especially gastrointestinal complaints) are much less likely when dosing instructions are followed correctly.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- None reported with a frequency exceeding 10% in pivotal osteoporosis trials at the 5 mg once-daily dose; adverse-event rates broadly matched placebo in the VERT and HIP studies.
Common
May affect up to 1 in 10 people
- Headache
- Dyspepsia (indigestion, heartburn)
- Nausea
- Abdominal pain
- Constipation
- Diarrhoea
- Feeling of fullness or bloating
- Musculoskeletal pain (joint pain, muscle pain, back pain)
Uncommon
May affect up to 1 in 100 people
- Oesophagitis (inflammation of the oesophagus), occasionally with ulceration or stricture
- Gastritis or duodenitis
- Iritis (inflammation of the iris of the eye)
- Abnormal liver function tests
Rare
May affect up to 1 in 1,000 people
- Glossitis (inflammation of the tongue)
- Oesophageal stricture
- Uveitis
Very Rare / Not Known
Reported from post-marketing surveillance
- Osteonecrosis of the jaw (ONJ)
- Osteonecrosis of the external auditory canal (ear)
- Atypical subtrochanteric or diaphyseal femoral fractures
- Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and bullous skin reactions
- Hypersensitivity and allergic reactions, including angio-oedema and, very rarely, anaphylaxis
- Severe hypocalcaemia, particularly in patients with untreated vitamin D deficiency or renal impairment
- Hair loss (alopecia)
Serious Adverse Events Requiring Urgent Attention
Although rare, several adverse events associated with bisphosphonates can be serious and warrant immediate medical attention:
- Severe oesophageal reactions: New or worsening dysphagia, pain on swallowing, retrosternal pain, severe heartburn or vomiting blood should prompt immediate discontinuation of Optinate and medical review.
- Osteonecrosis of the jaw (ONJ): Persistent pain in the jaw, a non-healing sore in the mouth, loose teeth, gum swelling or exposed bone warrant dental and medical assessment. The risk is very low with oral bisphosphonates given for osteoporosis but is substantially higher in patients receiving high-dose intravenous bisphosphonates for cancer.
- Atypical femoral fractures: New, dull or aching pain in the thigh, hip or groin – particularly if it precedes a low-trauma fracture – may indicate a stress reaction in the femoral shaft. Imaging and specialist review are required.
- Severe allergic reactions: Sudden swelling of the lips, tongue, throat or face; difficulty breathing; widespread rash or hives; or fainting require emergency care.
If you experience any side effects, including any not listed here, tell your doctor, nurse or pharmacist. You can also report suspected adverse reactions directly to your national pharmacovigilance authority – for example, the EudraVigilance system in Europe, the FDA MedWatch programme in the United States, or the MHRA Yellow Card scheme in the United Kingdom. These reports help regulators continue to monitor the long-term safety of Optinate.
How Should Optinate Be Stored?
Optinate 5 mg is supplied as a film-coated tablet in blister packs, typically containing 14, 28 or 30 tablets per pack. Proper storage helps preserve both the chemical stability and the physical integrity of the tablets.
- Temperature: Store below 25°C (77°F). Protect from extreme heat and sunlight. No refrigeration is required.
- Humidity: Store in a dry place. Keep tablets in the original blister packaging until the moment they are taken, as this protects them from moisture.
- Original packaging: Do not transfer tablets to a pill organiser unless it is kept in a cool, dry environment and used within a short period. Prolonged storage outside the blister may expose tablets to humidity and reduce shelf life.
- Expiry date: Do not use Optinate after the expiry date printed on the blister and on the outer carton. The expiry date refers to the last day of that month.
- Children and pets: As with all medicines, keep Optinate well out of reach of children and pets. Even a small number of bisphosphonate tablets can cause oral mucosal injury in a young child.
- Disposal: Do not throw unused Optinate tablets down the sink, toilet or into household waste. Return expired or unused tablets to your pharmacy for safe disposal; this helps protect the environment from pharmaceutical waste.
If a tablet has been cut, crushed or damaged, it should not be used – discard it and take a fresh intact tablet with the next scheduled dose.
What Does Optinate Contain?
Active Substance
The active substance is risedronate sodium. Each film-coated tablet contains 5 mg of risedronate sodium, equivalent to approximately 4.64 mg of risedronic acid. Risedronic acid is a nitrogen-containing bisphosphonate with the chemical name [1-hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid).
Inactive Ingredients (Excipients)
The tablet core typically contains:
- Lactose monohydrate
- Microcrystalline cellulose
- Crospovidone
- Magnesium stearate
The film coating typically contains:
- Hypromellose
- Macrogol (polyethylene glycol)
- Hydroxypropyl cellulose
- Titanium dioxide (E171) as a white colouring agent
- Colourants (iron oxide derivatives) to give the tablet its specific colour and to distinguish it from other strengths
Patients with rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take Optinate, because it contains lactose.
Appearance and Pack Sizes
Optinate 5 mg tablets are film-coated, typically oval or round in shape, coloured to distinguish them from higher-strength risedronate products, and embossed or debossed with an identifying marking. Each carton contains one or more blister strips, usually 14, 28 or 30 tablets per pack, packaged with a patient information leaflet in local language(s). Not all pack sizes may be marketed in every country.
Marketing Authorisation Holder and Manufacturer
Optinate is marketed in various countries under the brand name Optinate. In other markets, the same active substance is sold under different brand names, most notably Actonel. The marketing authorisation holder and the manufacturer vary by region; consult the patient information leaflet supplied with your specific product, which lists the authorised holder and the approved manufacturing sites for that market.
Frequently Asked Questions About Optinate
Optinate (risedronate sodium) 5 mg is used to treat and prevent osteoporosis in postmenopausal women and in men with low bone density at high risk of fracture. It is also used to prevent bone loss in patients starting or already receiving long-term systemic corticosteroid therapy, and to treat Paget's disease of bone. By reducing the activity of bone-resorbing cells (osteoclasts), it increases bone mineral density and lowers the risk of vertebral and hip fractures.
Take one Optinate 5 mg tablet first thing in the morning, at least 30 minutes before breakfast, any other drink (except plain water) or any other medicine. Swallow the tablet whole with a full glass (180–240 mL) of plain tap water while sitting or standing upright. Do not chew, crush or suck it. Remain upright – sitting, standing or walking – for at least 30 minutes after the dose. After this time, you may eat your normal breakfast and take other medicines, including calcium and vitamin D.
Lying down shortly after dosing increases the risk of the tablet or its dissolved contents remaining in contact with the oesophagus, which can cause irritation, ulceration or, rarely, stricture. If this happens once, rise to an upright position, drink more water, and watch for any new heartburn, chest pain or difficulty swallowing over the following days. If you develop such symptoms, stop Optinate and contact your doctor. If accidental recumbency is a recurring problem – for example because of morning pain or mobility issues – ask your doctor whether a weekly or monthly bisphosphonate regimen might suit you better.
Yes, and in fact most patients taking Optinate also take calcium and vitamin D supplements – but never at the same time of day. Calcium, magnesium, iron and antacids form insoluble complexes with risedronate in the gut and can virtually abolish its absorption. Take Optinate first thing in the morning with plain water and keep the 30-minute window clear. Take your calcium and vitamin D supplements later in the day, ideally with a meal, to maximise both their absorption and the effect of Optinate.
For osteoporosis, most guidelines recommend an initial treatment period of 3–5 years with a bisphosphonate such as risedronate, followed by a structured reassessment of fracture risk, bone mineral density, height loss and any new fractures. Patients who remain at high risk may continue for up to 10 years, while those whose risk has declined may be offered a drug holiday (a planned break in treatment) thanks to the long skeletal persistence of bisphosphonates. Treatment duration for Paget's disease is typically two months, with further courses only if the disease re-activates.
Osteonecrosis of the jaw (ONJ) is a rare but serious complication associated with bisphosphonates. The absolute risk with oral bisphosphonates used at osteoporosis doses is very low – estimated at around 1 in 10,000 to 1 in 100,000 patient-years – and substantially lower than the risk with high-dose intravenous bisphosphonates used in cancer care. Risk is increased by invasive dental procedures (extractions, implants), poor dental hygiene, pre-existing periodontal disease, smoking, concomitant corticosteroid therapy and diabetes. A dental review and completion of any needed dental work before starting Optinate, plus good oral hygiene during treatment, substantially reduce this risk.
Optinate contains risedronate sodium, while Fosamax and its generics contain alendronate sodium. Both are nitrogen-containing bisphosphonates that inhibit osteoclast-mediated bone resorption, and both are well-established first-line treatments for osteoporosis. They differ in their chemical structure, potency per milligram and dosing options. Head-to-head comparisons have generally shown comparable anti-fracture efficacy. Choice between them is guided by patient tolerance, available dosing schedules (daily, weekly or monthly), drug interactions and prescriber experience rather than by clear differences in efficacy.
References
- European Medicines Agency (EMA). Risedronate sodium – Summary of Product Characteristics. Last updated 2025. Available from: EMA website.
- U.S. Food and Drug Administration (FDA). Actonel (risedronate sodium) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial (VERT-NA). JAMA. 1999;282(14):1344–1352. doi:10.1001/jama.282.14.1344.
- Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis (VERT-MN). Osteoporos Int. 2000;11(1):83–91. doi:10.1007/s001980050010.
- McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women (HIP study). N Engl J Med. 2001;344(5):333–340. doi:10.1056/NEJM200102013440503.
- Kanis JA, Cooper C, Rizzoli R, Reginster J-Y; on behalf of the Scientific Advisory Board of ESCEO and the Committee of Scientific Advisors of IOF. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44. doi:10.1007/s00198-018-4704-5.
- Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16–35. doi:10.1002/jbmr.2708.
- Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. doi:10.1002/art.40137.
- Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies – comparative context for bisphosphonates. J Bone Miner Res. 2010;25(10):2256–2265.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. doi:10.1002/jbmr.2405.
- Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1–23. doi:10.1002/jbmr.1998.
- World Health Organization (WHO). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series. Geneva: WHO; 2021 (update).
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in endocrinology, rheumatology, internal medicine and clinical pharmacology.
Medical Content
iMedic Endocrinology & Metabolic Bone Editorial Team – specialist physicians in osteoporosis, metabolic bone disease and fracture prevention
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, IOF/ESCEO and ACR/ECTS guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, bisphosphonate pharmacokinetics and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.